Kronos Bio’s lanraplenib was granted FDA orphan designation as a treatment of Acute Myeloid Leukemia, or AML, according to a post to the agency’s website.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KRON:
- Kronos Bio Announces Top-Level Executives’ Departure
- Kronos Bio Announces Executive Leadership Changes and Severance Deals
- Kronos implements new leadership structure, eliminates CMO, CSO, COO roles
- Kronos Bio price target lowered to $6 from $7 at Piper Sandler
- Kronos Bio price target lowered to $2.50 from $9 at H.C. Wainwright
